![]() Efficacy of ICS add-on to LAMA/LABA on total adverse events. ![]() N.S. = not significant N.A. = not available from the original papers. Comparison of exacerbation rate in each trial. Summary of findings for the main comparison. Sub-analysis of trough FEV 1 by baseline blood eosinophil count (descriptive analysis). Sub-analysis of exacerbations by baseline blood eosinophil count (descriptive analysis). Baseline blood eosinophil count and moderate to severe COPD exacerbations in the past 12 months. Characteristics of included studies for the analysis of each outcome. List of studies excluded from the analysis. The Creative Commons Public Domain Dedication waiver ( ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Īdditional file 1: Table S1. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |